现在位置 >首页 > dubin98发表的所有文章
dubin98 ⁄ 发表于3年前 研究点评, 进展交流 [ICU Management & Practice]: 冲突地区的重症医学已关闭评论
Critical Care in Conflict Zones Conflict zones often involve gunfights, bomb blasts, and mass casualty incidents. However, pat......
dubin98 ⁄ 发表于3年前 研究点评, 进展交流 [NEJM发表论文]:强化免疫检查点在类风湿关节炎中的作用已关闭评论
EDITORIAL Reinforcing the Checkpoint in Rheumatoid Arthritis Ellen M. Gravallese, Ranjeny Thomas N Engl J Med 2023; 388:1905......
dubin98 ⁄ 发表于3年前 时讯速递, 进展交流 [BMJ发表论文]:同行审稿人对审稿邀请的反应已关闭评论
Research Analysis of peer reviewers’ response to invitations by gender and geographical region: cohort study of manuscripts review......
dubin98 ⁄ 发表于3年前 研究点评, 进展交流 [ICU Management & Practice]: 两次除颤优于一次?已关闭评论
Two Shocks Better Than One? In a recent investigation, the researchers aimed to answer whether alternative defibrillation stra......
dubin98 ⁄ 发表于3年前 指南导读, 进展交流 [JAMA临床指南精要]:ARDS患者的诊治:2023年ESICM临床实践指南总结已关闭评论
JAMA Clinical Guidelines Synopsis  June 17, 2023 Caring for Patients With Acute Respiratory Distress Syndrome: S......
dubin98 ⁄ 发表于3年前 时讯速递, 进展交流 [JAMA发表论文]:使用Ziritaxestat,一种自分泌运动因子抑制剂,与特发性肺间质纤维化的肺功能已关闭评论
Original Investigation  May 9, 2023 Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic P......
dubin98 ⁄ 发表于3年前 时讯速递, 进展交流 [NEJM Evid发表论文]:小剂量氢化可的松治疗成年感染性休克患者的患者水平meta分析已关闭评论
ORIGINAL ARTICLE Patient-Level Meta-Analysis of Low-Dose Hydrocortisone in Adults with Septic Shock Romain Pirracchio, Djillali......
dubin98 ⁄ 发表于3年前 研究点评, 进展交流 [ICU Management & Practice]: ARDS的生物标志物:有何进展?已关闭评论
ICU Management & Practice, Volume 23 - Issue 1, 2023 Biomarkers for ARDS. What is New? Despite several biomarkers havi......
dubin98 ⁄ 发表于3年前 时讯速递, 进展交流 [Lancet Infect Dis发表论文]:奈玛特韦-利托那韦预防新冠病毒感染患者住院和死亡的作用已关闭评论
ARTICLES|ONLINE FIRST Effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and deaths in people with COVID-19......
dubin98 ⁄ 发表于3年前 研究点评, 进展交流 [Nature发表文章]:科学家对统计学显著性提出质疑已关闭评论
COMMENT 20 March 2019 Scientists rise up against statistical significance Valentin Amrhein, Sander Greenland, Blake McShane a......
×
腾讯微博